In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects were seen when combining trial data, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.
Should Every ACL Get E-Stim? What the New NMES Meta-Analysis Really Shows
New meta-analysis: Early NMES after ACL surgery boosts quad strength. When and how should sports PTs use it? We break